NCT07047183View on ClinicalTrials.gov

Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions
Myelodysplastic NeoplasmsTransplantation
Interventions
DRUG

VEN (Venetoclax)

Enrolled patients will receive: Venetoclax: 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Days 3-14. Azacitidine: 75 mg/m² on Days 1-7. Cycle duration: 28 days Total cycles: 1 to 2 cycles

Trial Locations (1)

130000

RECRUITING

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Yehui Tan

OTHER

NCT07047183 - Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter